MYC

The bull case

1. 1.

   Overwhelming genetic dependency. DepMap mean gene effect -1.9871, essential in 95.2% of 1,208 models — among the strongest dependencies in the entire corpus.

   confidence: high·genetic_validation

2. 2.

   Surging, broad commercial interest. 100 patents across 180 organizations, with filing velocity 17 (2023) → 22 (2024) → 51 (2025); emerging_signals flags a patent surge. The field is intensifying its attack.

   confidence: high·competitive_landscape / emerging_signals

3. 3.

   Pathogenic footprint and deep literature. 43.5% of 8,341 variants pathogenic (hotspot residue 363); 253 curated papers.

   confidence: high·genetic_validation.variant_pathogenicity

The bear case

1. 1.

   Structurally undruggable — the defining fact. Despite 90 compounds and a 2025 patent surge, max clinical phase = 0: nothing has reached phase 1. MYC is a transcription factor with no enzymatic pocket; direct inhibition has, in this graph, zero clinical proof points.

   confidence: high·competitive_landscape.compound_phase_distribution

2. 2.

   Pan-essentiality = narrow window. The same 95.2% dependency that validates MYC means it is essential in normal proliferating tissue — the CHEK1 problem again: validation and therapeutic window are in tension.

   confidence: high·genetic_validation, interpreted

3. 3.

   Momentum into an undrugged target is a caution. 51 filings in 2025 against a target with no phase-1 asset reads as crowding/hope, not de-risking.

   confidence: moderate·competitive_landscape / emerging_signals

4. 4.

   No modality read. 100% of compounds unclassified — the graph cannot characterise the chemical strategies being tried.

   confidence: flagged·kg_native.modality_gaps

The non-consensus angleNo strong angle

No strong non-consensus signal in current data; MYC's profile matches its reputation. No DepMap co-essentiality fired and there is no independently multi-sourced whitespace node.

• The transcriptional machinery, but PPI-proxy only. The functional-coupling whitespace tool returns EP300, TRRAP, KAT2A, ZBTB17 (MIZ-1), BIN1, HIF1A (PPI 0.99+) — MYC's coactivator/cofactor apparatus. Of these, only HIF1A is in Mosaic's curated target set; it carries 0 patents and 0 compounds *in Mosaic's KG*, against 73 tracked papers — a statement about this KG's patent coverage for HIF1A, not about the real-world landscape, where the HIF pathway is actively pursued. EP300, TRRAP, KAT2A, ZBTB17 and BIN1 are outside curated coverage, so their patent/compound status is not assessed (not a whitespace claim). This hints at the 'drug the machinery, not MYC itself' strategy, but it is PPI-proxy, not co-essentiality, so it is not advanced.

  confidence: PPI-proxy — weak·kg_native.synthetic_lethal_whitespace (PPI-proxy)

  Patent / compound status: not assessed (out of coverage). gene outside Mosaic curated coverage (HIF1A excepted — in-set, 0 in this KG, which is a coverage statement not a landscape claim) — competitive landscape is a validated lead to verify externally, not a whitespace claim.

• Resistance/partner co-mentions are thin and consensus. MCL1 (2 papers; 156 patents), CHEK2/BRAF/KRAS (1 paper each) — co-mentions, heavily patented, not whitespace.

  confidence: body/mention·kg_native.resistance_bypass_map (curated)

What would change this thesis

• If any MYC-directed compound reaches phase 1, the central bear (structural undruggability) cracks and the validation finally has a chemistry on-ramp.
• If DepMap co-essentiality resolves a synthetic-lethal partner of MYC, the 'drug the machinery' angle upgrades from PPI-proxy to validated.
• If a tumor-selective MYC-dependency context is evidenced, the pan-essentiality/window bear weakens.